Table 4 Clinicopathological and molecular features of BRAF mutant colorectal cancers stratified according to methylator phenotype status.
CIMP- | CIMP+ | |||||
|---|---|---|---|---|---|---|
Feature | BRAF WT (n = 145) (%) | BRAF M (n = 5) (%) | P | BRAF WT (n = 31) (%) | BRAF M (n = 11) (%) | P |
Age (years) | 68.3 ± 13.5 | 71.0 ± 11.0 | NS | 71.7 ± 11.8 | 65.4 ± 26.3 | NS |
Females | 37 | 60 | NS | 42 | 45 | NS |
TILS + | 2 | 40 | 0.008 | 17 | 45 | 0.06 |
Node negative | 63 | 60 | NS | 65 | 82 | NS |
Proximal site | 35 | 60 | NS | 74 | 80 | NS |
Poor grade | 13 | 66 | 0.05 | 20 | 40 | NS |
Mucinous | 9 | 25 | NS | 25 | 45 | NS |
MSI+ | 6 | 20 | NS | 19 | 64 | 0.01 |
Dist. MLH1 methylated | 3 | 0 | NS | 42 | 64 | NS |
Prox. MLH1 methylated | 0 | 0 | NS | 23 | 55 | 0.05 |
KRAS mutant | 43 | 0 | 0.06 | 55 | 0 | 0.001 |
TP53 mutant | 26 | 0 | NS | 29 | 20 | NS |